Roxbury Financial LLC Invests $399,000 in Novartis AG (NYSE:NVS)

Roxbury Financial LLC bought a new stake in Novartis AG (NYSE:NVS - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 3,769 shares of the company's stock, valued at approximately $399,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NVS. Centaurus Financial Inc. raised its position in shares of Novartis by 1.7% during the 3rd quarter. Centaurus Financial Inc. now owns 5,728 shares of the company's stock worth $659,000 after purchasing an additional 98 shares during the last quarter. Clear Harbor Asset Management LLC grew its holdings in Novartis by 2.3% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 4,423 shares of the company's stock valued at $509,000 after buying an additional 100 shares during the last quarter. Allen Wealth Management LLC grew its holdings in Novartis by 1.8% during the 3rd quarter. Allen Wealth Management LLC now owns 5,788 shares of the company's stock valued at $666,000 after buying an additional 100 shares during the last quarter. WealthPlan Investment Management LLC grew its holdings in Novartis by 1.1% during the 3rd quarter. WealthPlan Investment Management LLC now owns 9,494 shares of the company's stock valued at $1,092,000 after buying an additional 100 shares during the last quarter. Finally, Avidian Wealth Enterprises LLC grew its holdings in Novartis by 1.3% during the 3rd quarter. Avidian Wealth Enterprises LLC now owns 7,913 shares of the company's stock valued at $910,000 after buying an additional 102 shares during the last quarter. Hedge funds and other institutional investors own 13.12% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Erste Group Bank reissued a "hold" rating on shares of Novartis in a research note on Tuesday, November 19th. Morgan Stanley began coverage on shares of Novartis in a research report on Wednesday, February 12th. They set an "underweight" rating on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Novartis from a "hold" rating to a "buy" rating in a research report on Tuesday, February 4th. BMO Capital Markets raised their target price on shares of Novartis from $118.00 to $120.00 and gave the stock a "market perform" rating in a research report on Wednesday, October 30th. Finally, StockNews.com upgraded Novartis from a "buy" rating to a "strong-buy" rating in a research note on Saturday, February 8th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $123.38.

Novartis Trading Up 0.2 %

Shares of NVS stock traded up $0.20 on Wednesday, reaching $106.81. 486,886 shares of the stock were exchanged, compared to its average volume of 1,919,267. The stock has a market cap of $218.32 billion, a P/E ratio of 18.16, a price-to-earnings-growth ratio of 1.68 and a beta of 0.58. The company has a quick ratio of 0.84, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. The firm has a 50 day moving average of $100.91 and a two-hundred day moving average of $108.16. Novartis AG has a 1-year low of $92.35 and a 1-year high of $120.92.

Novartis (NYSE:NVS - Get Free Report) last released its quarterly earnings data on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, beating the consensus estimate of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. On average, research analysts anticipate that Novartis AG will post 8.44 EPS for the current year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.